TSC1 and TSC2: The Brake Upstream of mTORC1

How the Complex Works

TSC1 (hamartin) and TSC2 (tuberin) form a complex, with a third subunit TBC1D7. TSC2 acts as a GTPase-activating protein for the small GTPase RHEB, keeping RHEB in its inactive GDP-bound state.

Active, GTP-bound RHEB is required to switch on mTORC1 at the lysosome. So when the TSC complex is working, mTORC1 is held down; when it is lost, RHEB stays active and mTORC1 signalling runs high.

Integrating Signals

The TSC complex is a signal-integration hub. Growth-factor signalling through AKT and ERK phosphorylates TSC2 to inhibit it, favouring growth. Energy stress activates AMPK, which phosphorylates TSC2 to strengthen the brake and shut mTORC1 down.

This lets a single complex reconcile pro-growth and stress signals before they reach mTORC1.

Tuberous Sclerosis Complex

Germline loss-of-function variants in TSC1 or TSC2 cause tuberous sclerosis complex, an autosomal dominant condition with benign tumours in the brain, skin, heart, lungs and kidneys, along with epilepsy and neuropsychiatric features.

mTOR inhibitors (everolimus, sirolimus) are approved for several TSC manifestations, including subependymal giant cell astrocytoma, renal angiomyolipoma and lymphangioleiomyomatosis, because these lesions are directly driven by unrestrained mTORC1.

TSC Loss in Sporadic Cancer

Somatic TSC1 or TSC2 alterations occur in a minority of bladder cancers, renal tumours including a subset with high mTORC1 activity, and other cancers. Case reports and small series have described responses to mTOR inhibitors in TSC-altered tumours.

The evidence is strongest as a biological rationale; TSC status is not a broadly validated predictive biomarker across tumour types.

Interpretation Notes

A TSC1 or TSC2 variant should be classified for pathogenicity and assessed for whether it is germline or somatic, since a germline finding has implications for the individual and family that a somatic tumour finding does not.

Loss of the second allele in a tumour is relevant to whether the pathway is actually deregulated.

Key Takeaways

• ·TSC1-TSC2 inactivates RHEB and is the main brake on mTORC1.
• ·AKT and ERK release the brake; AMPK reinforces it under energy stress.
• ·Germline TSC1/TSC2 loss causes tuberous sclerosis, where mTOR inhibitors are approved for specific lesions.
• ·Somatic TSC loss is a biological rationale for mTOR inhibition, not a validated pan-cancer biomarker.